Weekly shot · weight loss · in late trials
A weekly shot that helped people in trials lose about a quarter of their weight. Whether you are curious, starting, or already on it, here is what helps.

Status as of November 17, 2026. For information only, not medical advice: read the medical disclaimer.
Where are you with Retatrutide?
Good place to start. Here is what we would want to know before deciding, in plain words.
Retatrutide is still in trials. The only legal ways to get it are joining a trial, or a special access programme your doctor applies for. Lilly plans to ask the FDA for approval in early 2027.
In the biggest trial, people on the top dose lost about a quarter of their weight over 80 weeks. People on placebo lost about 4%.
Stomach upset was the most common side effect: about 4 in 10 felt sick at some point (1 in 7 on placebo). About 1 in 9 stopped because of side effects.
The FDA has warned sellers of “research use only” retatrutide. What is in those vials cannot be checked, so trial results do not describe them.
Coming Pick your questions and print them as one page.
The first weeks are where most people struggle. Here is what the trials saw and what the label of a similar approved drug advises.
Everyone in the big trials began on a low dose that went up every 4 weeks. Starting lower partly cut stomach side effects. This describes the trials, not a plan for you: dose decisions belong with your prescriber.
The calculator turns the numbers on a label into units on a U-100 syringe. It never suggests a dose.
The label of a related approved drug covers injection spots, sharing needles, food and your medicines list.
Weight, waist and a photo on day one make it much easier to see change later.
Coming A progress log that stays only on your device.
You’re on it. Here’s how to feel better day to day, and how to tell if it’s working.
Drink fluids, and tell your provider if it is severe or will not go away.
Odd skin feelings were reported more often on retatrutide than placebo in every large trial, in up to about 1 in 5 people on the top dose. Nobody has explained why yet. Mention it to your doctor.
In trials, weight was still falling between weeks 24 and 48, so early weeks rarely tell the whole story. Look at your weekly average, not one day.
No trial has tested a switch to retatrutide, so nobody can say from evidence how to do it. Plan any switch with your prescriber.
No judgement. We won’t tell you where to buy or how much to take, but these steps lower the risk whatever you use:
Most side effects are mild and fade. A few need a call today, and a few need help right now. Here is how to tell them apart.
Emergency: call 911 (or your local emergency number). Possible overdose or wrong amount: Poison Help, 1-800-222-1222, free and open 24 hours. Report a bad reaction to the FDA through MedWatch.
Every number below says what kind of study it came from. Bracketed numbers point to the sources listed at the end.
In the large trials, everyone started on a low dose. The dose went up every 4 weeks. The top dose began in week 17. This was the trial plan, not a plan for you.
Company press releaseLilly press releases, 2026-05-21 and 2025-12-11In a small study of 72 people with type 2 diabetes, the group that stepped up to the top dose lost about 9 kg more than placebo (8.96 kg).
Small human study[3]In the phase 2 trial, the top-dose group had lost 17.5% of their weight on average.
Human randomised trial[4]By week 48, the same group had lost 24.2%, so weight was still falling between weeks 24 and 48.
Human randomised trial[4]In TRIUMPH-1, people on the top dose lost 25.0% on average. People on placebo lost 3.9%.
Human randomised trial[5]In a group with a BMI of 35 or more who kept going to two years, the top-dose group reached 30.3% (efficacy estimand).
Company press releaseLilly press release, 2026-05-21Averages from trials, not a forecast for you. Each step comes from a different trial or time point, so the steps are not one curve. Sources: step-up plan, Lilly releases for TRIUMPH-1 (2026-05-21) and TRIUMPH-4 (2025-12-11); week 12[3]; weeks 24 and 48[4]; week 80[5]; week 104, Lilly release 2026-05-21.
The papers and releases we read do not say in which weeks stomach side effects started or eased. They also do not report day-by-day effects, so we leave those out.
Use a new spot with each weekly shot. You can use the same area of your body, but not the same spot.
It can be taken with or without food.
Not even with a new needle. You could pass on or catch a serious infection.
Diarrhoea, nausea and vomiting can make you lose fluids. Drinking fluids helps lower the chance of dehydration, which can harm your kidneys.
Tell your provider about stomach problems that are severe or will not go away.
The risk may be higher if you also take insulin or a sulfonylurea. Signs include shakiness, sweating, dizziness, headache, confusion and hunger.
Show it to your provider and pharmacist when you get a new one.
Food can get into the lungs during procedures that put you to sleep. Tell all your providers before any surgery.
Every tip comes from the Zepbound (tirzepatide) Medication Guide[2], revised 08/2026. Tirzepatide is a related approved medicine that acts on two of the same receptors. Retatrutide has no label of its own, no study has tested these tips with retatrutide, and nothing here is advice to change a dose.
We have not added advice on what to eat when your appetite drops. We will only add it from published guidance, with the source named.
These warning signs come from the Zepbound (tirzepatide) Medication Guide[2], revised 08/2026, a related approved medicine. Retatrutide has no label of its own, so these are not retatrutide warnings.
These are ways to keep a record. They are not targets, and they do not replace checks by your prescriber.
Trials cannot explain one person's result, and this section does not offer troubleshooting. It reports what the trials show about how much results varied, how long the doses took to reach the top step, and what is unknown.
| Arm | ≥5% lost | ≥10% lost | ≥15% lost |
|---|---|---|---|
| 4 mg | 92% | 75% | 60% |
| 8 mg | 100% | 91% | 75% |
| 12 mg | 100% | 93% | 83% |
| Placebo | 27% | 9% | 2% |
Phase 2 obesity trial, share of people who reached each amount of weight loss at 48 weeks. Source: NEJM 2023[4].
Results varied between people. Even on 12 mg in phase 2, 17% did not reach 15% weight loss (table above). In TRIUMPH-1, 15.3%, 37.9% and 45.3% (4 / 9 / 12 mg) lost 30% or more, vs 0.5% on placebo (efficacy estimand, Lilly press release 2026-05-21).
No published or registered trial has tested switching from tirzepatide (Mounjaro, Zepbound) or semaglutide to retatrutide. Phase 3 trials excluded people who had taken a weight-loss drug in the 90 days before screening[6][7]. So there is no trial evidence on how to switch, what dose to start at after tirzepatide, or what to expect.
Retatrutide is a single peptide molecule made by Eli Lilly that activates the GIP, GLP-1 and glucagon receptors[8]. In trials it is injected under the skin once a week.
Other names. Lilly's code name is LY3437943[8]. "Reta" is the community short name, and "retratrutide" is a common misspelling. PubChem lists the sodium salt with the formula C221H342N46O68 (PubChem CID 171934787).
Why once a week. In a phase 1b study of 72 people with type 2 diabetes, retatrutide had a half-life of about 6 days, and blood levels rose in proportion to the dose, which the authors say supports weekly dosing[3].
Retatrutide is one molecule that binds three receptors. GIP and GLP-1 are gut hormones that act on appetite and insulin release. Glucagon is a hormone from the pancreas. Some of what is said about the glucagon part online comes from mice, so the table shows where each finding was made.
| Finding | Where it was shown | Source |
|---|---|---|
| Activates GIP, GLP-1 and glucagon receptors | Cells | [8] |
| More activity at the GIP receptor; balanced activity at the glucagon and GLP-1 receptors | Cells | [8] |
| Glucagon receptor adds extra energy use on top of eating less | Obese mice only | [8] |
| Body weight falls with dose | People: phase 2 and phase 3 RCTs | [4][5] |
Does retatrutide burn fat? The extra energy use from the glucagon receptor was shown in obese mice[8]. No human study we found shows that retatrutide burns fat directly. What has been measured in people is body composition, covered in muscle and body composition.
Tirzepatide acts on two of the same receptors (GIP and GLP-1). Retatrutide adds the glucagon receptor. For trial results side by side, see retatrutide vs tirzepatide.
No. As of 2026-11-17 retatrutide has not been approved by the FDA or any other regulator (Lilly press release on TRANSCEND-T2D-2, 2026-10-28). Lilly says it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027 (Lilly releases, 2026-07-23 and 2026-09-29). Lilly releases up to 2026-11-14 do not announce that the application has been sent.
Lilly scientists publish the molecule and how it acts on three receptors.
Coskun et al., Cell Metab[8] CellPhase 1b study in type 2 diabetes (72 people) reports a half-life of about 6 days.
Urva et al., Lancet[3] Small human studyPhase 2 obesity trial (338 people) published: up to −24.2% at 48 weeks.
Jastreboff et al., NEJM[4] Human randomised trialFirst phase 3 readout: TRIUMPH-4 (obesity with knee osteoarthritis).
Lilly press release[9] Company press releaseTRIUMPH-2 and TRIUMPH-3 toplines; Lilly says it plans to submit a BLA in Q1 2027.
Lilly press release[12] Company press releaseTRIUMPH-1 published in NEJM; TRIUMPH-2 published in the Lancet the same day.
Jastreboff et al., NEJM[5] Human randomised trialFDA page states retatrutide cannot be used in compounding under federal law.
FDA: concerns with unapproved GLP-1 drugs[13] RegulatorTRANSCEND-T2D-2, the first head-to-head trial (vs Ozempic 2 mg), topline announced.
Lilly press release[14] Company press releaseTRIUMPH-4 and the TRIUMPH-1 knee osteoarthritis results published in NEJM.
Schnitzer et al., NEJM[15] Human randomised trialExpanded access. Lilly lists a single-patient expanded access programme for adults with a BMI of 35 or more, at least two serious obesity complications, no response to the best approved treatment, and no way to join a trial. The treating doctor makes the request[10]. Outside this programme, the only legal way to receive retatrutide is in a trial.
Is there a retatrutide pen or price? No. There is no approved retatrutide product, so there is no approved pen, label or price. Trials give the drug as a weekly injection under the skin.
Compounding. The FDA says: "Retatrutide and cagrilintide cannot be used in compounding under federal law." It also says they are not components of FDA-approved drugs and have not been found safe and effective for any condition[13].
Lilly reports two weight numbers for each trial arm. The efficacy estimand assumes everyone stayed on the drug; it is the larger number and the one in headlines. The treatment-regimen estimand counts everyone who was randomised, including people who stopped; the NEJM and Lancet papers lead with it. Each figure below says which one it is.
Scale: 0–28.3%
Adults with obesity and no diabetes, n=2,339. Treatment-regimen figures: NEJM 2026[5]. Efficacy figures: Lilly press release, 2026-05-21. Bars show weight lost, so larger is more weight lost.
| Trial | Who took part | n | Weeks | Weight change by arm | Source |
|---|---|---|---|---|---|
| Phase 1b | Type 2 diabetes | 72 | 12 | Up to −8.96 kg vs placebo (3→6→9→12 mg) | [3] |
| Phase 2 | Obesity | 338 | 48 | 1 mg −8.7%, 4 mg −17.1%, 8 mg −22.8%, 12 mg −24.2% vs placebo −2.1% | [4] |
| Phase 2 | Type 2 diabetes | 281 | 36 | −3.19% (0.5 mg) to −16.94% (12 mg) vs placebo −3.00% | [16] |
| TRIUMPH-1 | Obesity, no diabetes | 2,339 | 80 | TR: −17.6 / −23.7 / −25.0% vs −3.9%. Eff: −19.0 / −25.9 / −28.3% vs −2.2% (4 / 9 / 12 mg) | [5]; Lilly 2026-05-21 |
| TRIUMPH-2 | Obesity with type 2 diabetes | 1,152 | 80 | TR: −11.9 / −16.8 / −18.8% vs −5.1%. Eff: −12.7 / −19.1 / −20.8% vs −4.0% | [17]; Lilly releases |
| TRIUMPH-3 | BMI 35+ with heart disease | 1,949 | 80 | Eff: −21.6% (9 mg), −22.6% (12 mg) vs −3.2% | Lilly press release 2026-07-23[12] |
| TRIUMPH-4 | Obesity with knee osteoarthritis | 445 | 68 | TR: −20.0 / −23.7% vs −4.6%. Eff: −26.4 / −28.7% vs −2.1% (9 / 12 mg) | [15]; Lilly 2025-12-11 |
| TRANSCEND-T2D-1 | Type 2 diabetes, diet and exercise only | 537 | 40 | TR: −11.5 / −13.9 / −15.3% vs −2.6%; HbA1c −1.69 to −1.94 vs −0.81 | [11] |
| TRANSCEND-T2D-2 | Type 2 diabetes, open-label vs Ozempic 2 mg | 1,298 | 80 | Eff: −19.5% (9 mg), −20.9% (12 mg) vs −9.4% (Ozempic) | Lilly press release 2026-10-28[14] |
One row per trial. TR = treatment-regimen estimand; Eff = efficacy estimand. Results from different trials differ in population, length and estimand, so they are not a head-to-head comparison.
Do you need to stay on it? TRIUMPH-6 is testing what happens to weight when people stay on retatrutide or switch to placebo after 80 weeks[18]. It has no results yet; primary completion is estimated for 2028-04.
| Trial and source | Dose tested and how it was reached | Weeks | Weight change |
|---|---|---|---|
| Phase 1b T2D | 0.5, 1.5, 3 mg; 3→6 mg; 3→6→9→12 mgFixed or stepped as named | 12 | Up to −8.96 kg vs placebo (3→6→9→12 mg) |
| Phase 2 obesity | 1 mgFixed | 48 | −8.7% |
| Phase 2 obesity | 4 mgTwo arms: start 2 mg, or start 4 mg | 48 | −17.1% (both 4 mg arms) |
| Phase 2 obesity | 8 mgTwo arms: start 2 mg, or start 4 mg | 48 | −22.8% (both 8 mg arms) |
| Phase 2 obesity | 12 mgStart 2 mg | 48 | −24.2% |
| Phase 2 obesity | Placebo– | 48 | −2.1% |
| Phase 2 T2D | 0.5 mgFixed | 36 | −3.19% |
| Phase 2 T2D | 4 mgStart 2 mg | 36 | −7.92% |
| Phase 2 T2D | 4 mgNo escalation | 36 | −10.37% |
| Phase 2 T2D | 8 mg (slow)Start 2 mg | 36 | −16.81% |
| Phase 2 T2D | 8 mg (fast)Start 4 mg | 36 | −16.34% |
| Phase 2 T2D | 12 mgStart 2 mg | 36 | −16.94% |
| Phase 2 T2D | Placebo / dulaglutide 1.5 mgComparators | 36 | −3.00% / −2.02% |
| TRIUMPH-1 | 4 mg2 → 4 mg, step every 4 weeks | 80 | −17.6% TR / −19.0% Eff |
| TRIUMPH-1 | 9 mg2 → 4 → 6 → 9 mg | 80 | −23.7% TR / −25.9% Eff |
| TRIUMPH-1 | 12 mg2 → 4 → 6 → 9 → 12 mg | 80 | −25.0% TR / −28.3% Eff |
| TRIUMPH-1 | Placebo– | 80 | −3.9% TR / −2.2% Eff |
| TRIUMPH-1 extension | 4 mg → MTD; 9 mg → MTD; 12 mg → MTDBMI 35+, n=532 | 104 | −27.9 / −29.5 / −30.3% Eff |
| TRIUMPH-1 extension | Placebo → retatrutideBMI 35+ | 104 | −19.2% Eff |
| TRIUMPH-2 | 4 / 9 / 12 mgSame scheme as TRIUMPH-1 | 80 | −11.9 / −16.8 / −18.8% TR |
| TRIUMPH-2 | Placebo– | 80 | −5.1% TR |
| TRIUMPH-3 | 9 / 12 mgStart 2 mg, step every 4 weeks | 80 | −21.6 / −22.6% Eff |
| TRIUMPH-3 | Placebo– | 80 | −3.2% Eff |
| TRIUMPH-4 | 9 mg2 → 4 → 6 → 9 mg | 68 | −20.0% TR / −26.4% Eff |
| TRIUMPH-4 | 12 mg2 → 4 → 6 → 9 → 12 mg | 68 | −23.7% TR / −28.7% Eff |
| TRIUMPH-4 | Placebo– | 68 | −4.6% TR / −2.1% Eff |
| TRANSCEND-T2D-1 | 4 / 9 / 12 mgNot stated in the abstract | 40 | −11.5 / −13.9 / −15.3% vs −2.6% placebo |
| TRANSCEND-T2D-2 | 9 / 12 mg vs Ozempic 2 mgStart 2 mg, step every 4 weeks | 80 | −19.5 / −20.9% vs −9.4% Eff |
All arms were once weekly, under the skin. TR = treatment-regimen estimand; Eff = efficacy estimand. Phase 2 figures are least-squares means. The 104-week rows are an extension of TRIUMPH-1 in people with a BMI of 35 or more; "MTD" is the term Lilly used for the dose people moved to.
How the phase 3 trials stepped up. Lilly's releases for TRIUMPH-1 (2026-05-21) and TRIUMPH-4 (2025-12-11) say every arm started at 2 mg and increased every four weeks; the TRIUMPH-2 and TRIUMPH-3 releases give the same start and interval. The table shows that trial scheme. It is a description of the trials, not a schedule to follow.
| Trial weeks | Weekly dose given | Arms that stopped here |
|---|---|---|
| 1 to 4 | 2 mg | |
| 5 to 8 | 4 mg | 4 mg arm |
| 9 to 12 | 6 mg | |
| 13 to 16 | 9 mg | 9 mg arm |
| 17 onward | 12 mg | 12 mg arm |
Source: Lilly press releases for TRIUMPH-1 (2026-05-21) and TRIUMPH-4 (2025-12-11). Each step lasted 4 weeks.
How many mg per week did trial participants take? In phase 3, the weekly maintenance arms were 4, 9 and 12 mg, reached by the steps above. Phase 2 also tested 0.5, 1 and 8 mg arms. These are facts about the trials and not an amount anyone should take.
This tool converts the numbers on a vial label into concentration and U-100 syringe units. A worked example with no dose in it: 10 mg dissolved in 2 mL of water gives 5 mg per mL. The amount of water you add does not change how much drug is in the vial; it only changes how much each unit contains. That is the whole answer to "how much bac water for a 30 mg vial": the volume is a choice, and the calculator shows what each choice means.
Your answer is saved only in this browser so you are not asked again. See the privacy policy.
The 10, 20 and 30 mg presets are vial label sizes people search for. They are not doses, and no trial gave these amounts. Mixing steps: how to reconstitute peptides and bacteriostatic water. Full tool: reconstitution calculator.
In TRIUMPH-1, on the top dose (12 mg) about 4 in 10 people had nausea, vs about 1 in 7 on placebo (42.4% vs 14.8%). About 1 in 3 had diarrhoea (32.0% vs 13.5%). About 1 in 4 vomited (25.3% vs 4.8%). About 1 in 9 stopped because of side effects, vs 1 in 20 on placebo (11.3% vs 4.9%). Source: Lilly release, 2026-05-21[6]. What helps is in living with it day to day; warning signs are in when to call a doctor.
Stomach and gut effects were the most common side effects in every trial. In phase 2 they were dose-related, mostly mild to moderate, and partly reduced by starting at 2 mg instead of 4 mg[4]. Each trial reported its own figures, so each trial gets its own table below.
Scale: 0–42.4%
Source: Lilly press release on TRIUMPH-1, 2026-05-21 (company press release; trial record[6]). All three doses are in the table below.
| Event | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
| Nausea | 28.6 | 38.4 | 42.4 | 14.8 |
| Diarrhoea | 25.2 | 34.1 | 32.0 | 13.5 |
| Constipation | 23.8 | 25.9 | 26.1 | 10.9 |
| Vomiting | 10.6 | 22.8 | 25.3 | 4.8 |
| Dysesthesia | 5.1 | 12.3 | 12.5 | 0.9 |
| Urinary tract infection | 7.5 | 8.8 | 8.4 | 5.3 |
TRIUMPH-1, 80 weeks, % of people. Source: Lilly press release, 2026-05-21; trial record[6].
| Event | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
| Diarrhoea | 27 | 34 | 34 | 13 |
| Nausea | 14 | 21 | 28 | 8 |
| Low blood pressure | 1 | 5 | 6 | <1 |
| Dysesthesia | 4 | 6 | 7 | 1 |
TRIUMPH-2 (obesity with type 2 diabetes), 80 weeks, % of people. Source: Lancet 2026[17].
| Event | 9 mg | 12 mg | Placebo |
|---|---|---|---|
| Diarrhoea | 30.1 | 24.4 | 8.7 |
| Nausea | 21.7 | 22.4 | 5.8 |
| Dysesthesia | 6.4 | 6.4 | 1.3 |
TRIUMPH-3 (heart disease), 80 weeks, % of people. Source: Lilly press release, 2026-07-23; trial record[12]. Not yet peer-reviewed.
| Event | 9 mg | 12 mg | Placebo |
|---|---|---|---|
| Nausea | 38.1 | 43.2 | 10.7 |
| Diarrhoea | 34.7 | 33.1 | 13.4 |
| Vomiting | 20.4 | 20.9 | 0.0 |
| Constipation | 21.8 | 25.0 | 8.7 |
| Dysesthesia | 8.8 | 20.9 | 0.7 |
TRIUMPH-4 (knee osteoarthritis), 68 weeks, % of people. Source: Lilly press release, 2025-12-11; trial record[9].
Skin sensitivity (dysesthesia). Dysesthesia is the trial term for unusual skin sensations such as burning, tingling or sensitivity to touch. It is reported more often with retatrutide than with placebo in every phase 3 trial above: from 4% (TRIUMPH-2, 4 mg) to 20.9% (TRIUMPH-4, 12 mg), against 0.7% to 1.3% on placebo. The sources above report how often it happened. None of them explains why it happens, and we do not guess.
Scale: 0–20.9%
Each bar comes from a different trial with different people and lengths, so the bars are not a comparison between trials. Sources: Lilly releases for TRIUMPH-1 (2026-05-21), TRIUMPH-3 (2026-07-23) and TRIUMPH-4 (2025-12-11); Lancet[17] for TRIUMPH-2.
Heart rate and blood pressure. In phase 2, heart rate rose with dose, peaked at week 24 and then declined[4]. In TRIUMPH-2, low blood pressure was reported in 1%, 5% and 6% (4 / 9 / 12 mg) vs under 1% on placebo[17].
| Trial | Retatrutide arms | Placebo | Source |
|---|---|---|---|
| TRIUMPH-1 | 4.1% / 6.9% / 11.3% (4 / 9 / 12 mg) | 4.9% | Lilly 2026-05-21[6] |
| TRIUMPH-2 | 4% / 12% / 8% (4 / 9 / 12 mg) | 5% | [17] |
| TRIUMPH-3 | 9.8% / 13.5% (9 / 12 mg) | 4.8% | Lilly 2026-07-23[12] |
| TRIUMPH-4 | 12.2% / 18.2% (9 / 12 mg) | 4.0% | Lilly 2025-12-11[9] |
| TRANSCEND-T2D-1 | 2% to 5% | 0% | [11] |
| TRANSCEND-T2D-2 | 4.8% / 7.9% (9 / 12 mg) | 2.7% (Ozempic, no placebo arm) | Lilly 2026-10-28[14] |
People who stopped treatment because of side effects. In TRIUMPH-4, Lilly says rates tracked starting BMI and included people who stopped because of what they saw as too much weight loss. TRIUMPH-2 counts stopping for side effects or death.
Low blood sugar. No severe hypoglycaemia was reported in the phase 2 diabetes trial[16] or in TRANSCEND-T2D-1[11].
The only published body-composition data come from a DXA scan substudy of the phase 2 type 2 diabetes trial, with 103 people who finished it. At 36 weeks, total fat mass fell 23.2% on 12 mg vs 4.5% on placebo. The authors say the share of weight lost as lean mass was similar to other obesity treatments[22].
No trial has compared lean-mass loss on retatrutide with tirzepatide, so there is no evidence that it protects muscle better. No trial has tested whether it helps build muscle. For the cross-trial picture, see retatrutide vs tirzepatide.
The FDA says retatrutide is not a component of any FDA-approved drug and has not been found safe and effective for any condition. Its warning letters have gone to telehealth firms marketing retatrutide, ingredient distributors selling it to compounders, outsourcing facilities repackaging it, and sellers labelling it "for research purposes" or "not for human consumption"[13]. Two examples: GenoGenix LLC repackaged semaglutide, tirzepatide and retatrutide (FDA warning letter 718739, 2026-01-20), and Gram Peptides sold "Retatrutide" labelled "Research Use Only" (FDA warning letter 721806, 2026-03-31).
BioPharma Dive reported on 2026-08-12 that Lilly had filed six lawsuits, against a compounding pharmacy, a wellness business and four "research use only" sellers. A JAMA news feature covers online retatrutide sales[23]. Because these products are not the trial drug, trial results and side-effect rates do not describe them.
What people who bought it report. A study of Reddit posts from 7,823 people who said they used non-approved retatrutide could not verify what they took or how much. The most-reported effect was increased appetite (17.1%). These are self-reports, not side-effect rates[24].
The only legal routes are a clinical trial or the expanded access programme described in status and timeline.
| Trial | Registry | Phase | What it tests | People | Primary completion |
|---|---|---|---|---|---|
| TRIUMPH-5 | [7] | 3 | Retatrutide vs tirzepatide, obesity; weight at week 80 | ~800 | 2026-11 |
| TRIUMPH-6 | [18] | 3 | Keeping weight off: 80-week lead-in, then dose 1, dose 2 or placebo for 36 weeks | 643 | 2028-04 |
| TRIUMPH-7 | [25] | 3 | Chronic low back pain | 586 | 2027-09 |
| TRIUMPH-8 | [26] | 3b | Placebo-controlled, 56 weeks | 250 | 2027-06 |
| TRIUMPH-9 | [27] | 3b | Three dose-escalation schemes, week 104 | 600 | 2028-10 |
| TRANSCEND-T2D-3 | [28] | 3 | Type 2 diabetes with moderate or severe kidney impairment, on basal insulin | 341 | 2026-10-26 |
| Heart and kidney outcomes | [21] | 3 | Major heart and kidney events, about 5 years | ~10,000 | 2029-02 |
| MASLD master protocol | [29] | 3 | Fatty liver disease, several drugs | ~4,500 | 2030-08 |
| GZBF | [30] | 2 | New dose-escalation study, 1 to 12 mg arms | – | 2027-03 |
Read from ClinicalTrials.gov on 2026-11-17. Completion dates are the registry's estimates for primary completion.
TRIUMPH-5 is the only head-to-head trial against tirzepatide. This page and the comparison article will be updated when it reports.
Tirzepatide (Mounjaro, Zepbound). No trial has compared them head to head and reported yet. TRIUMPH-5 is doing that now[7]; each drug's own results are side by side in retatrutide vs tirzepatide.
Semaglutide (Ozempic). The only head-to-head result so far is TRANSCEND-T2D-2 in type 2 diabetes: −20.9% weight on retatrutide 12 mg vs −9.4% on Ozempic 2 mg at 80 weeks (efficacy estimand, open-label, Lilly press release 2026-10-28, not yet peer-reviewed)[14].
No published trial has combined retatrutide with MOTS-c, cagrilintide, BPC-157 or tirzepatide.